Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab

Summary

IMC-C103C is an immune mobilizing monoclonal T cell receptor against cancer (ImmTAC ®) designed for the treatment of cancers positive for the tumor-associated antigen MAGE-A4. This is a first-in-human trial designed to evaluate the safety and efficacy of IMC-C103C in adult patients who have the appropriate HLA-A2 tissue marker and whose cancer is positive for MAGE-A4.

Timeline

Start

2019-05-17

Primary completion

2023-09-25

Completion

2023-09-25

Drugs

Indications